Pharmaceutical savings after gastric bypass surgery.
Clinically severe obesity (CSO) is a surgically treated disease. The Roux-en-Y gastric bypass (RYGBP) has been used to treat patients with CSO and has resulted in an improvement in co-morbidities. We speculated that after a period of weight loss, patients would require less medication, resulting in cost-savings to both the patient and the insurance company, as well as an overall gain in health. A retrospective study was performed which involved the first 100 patients who had undergone RYGBP at a community-teaching hospital. Analysis of the data was conducted by the Wilcoxon signed rank test. 64 patients met our inclusion criteria and had adequate follow-up data available. The mean BMI was 57 kg/m(2) (range 36.6- 85.4 kg/m(2)), the female to male ratio was 4:1 (51:13), and the mean age was 44 years (range 27-64). The average monthly medication expenditure was reduced from US dollars 317 (SEM 47.25, range US dollars 23.12-US dollars 1801.19) preoperatively, to US dollars 135 (SEM 35.35, range US dollars 0.00-US dollars 1122.72) postoperatively. This reduction is significant (P <0.01). Weight loss after RYGBP leads to a significant reduction in medication expenses. These medication savings offset the costs of the initial procedure and represent permanent financial savings for the patient and society.